IP Library Granted Patent US 7,090,847
Granted Patent B1
US 7,090,847 · App. 09/658,699 · Granted Aug 15, 2006

Mammalian cytokines; related reagents and methods

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,090,847
App. No.
09/658,699
Granted
Aug 15, 2006
Kind
B1
Abstract

Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.

Claims (21)

1. A method for preparing an antibody or a fragment thereof that comprises the antigen binding site of the antibody, wherein said antibody binds to:

(i) a mammalian IL-B30/p40 complex comprising an IL-B30 subunit (SEQ ID NO:2 or 4) and a p40 subunit (SEQ ID NO:6 or 8), or

(ii) a fusion protein comprising the IL-B30 subunit (SEQ ID NO:2 or 4) and the p40 subunit (SEQ ID NO:6 or 8);

said method consists of:

(a) raising an antibody to said IL-B30/p40 complex or a polypeptide that comprises at least 11 contiguous amino acids from said p40 subunit and at least 11 contiguous amino acids from the IL-B30 subunit,

(b) confirming that said antibody binds to the IL-B30/p40 complex or fusion protein; and

(c) optionally preparing said fragment from said antibody.

2. The method of claim 1 , wherein said antibody or fragment thereof is a humanized antibody, monoclonal antibody, single chain antibody, Fv fragment, Fab fragment, Fab′ fragment, or F(ab′)2 fragment.

3. The method of claim 1 , wherein said antibody is a neutralizing antibody.

4. The method of claim 1 , wherein the fusion protein comprises, from the N-terminus to the C-terminus, mature IL-12 p40, a linker, and mature IL-B30.

5. A method of selecting an antibody or fragment thereof that specifically binds to:

(i) a mammalian IL-B30/p40 complex comprising an IL-B30 subunit (SEQ ID NO:2 or 4) and a p40 subunit (SEQ ID NO:6 or 8), or

(ii) a fusion protein comprising the IL-B30 subunit (SEQ ID NO:2 or 4) and the p40 subunit (SEQ ID NO:6 or 8);

wherein the antibody or fragment thereof does not bind the IL-B30 or p40 subunit alone, said method comprising

(a) providing candidate antibodies or fragments thereof that bind to the IL-B30/p40 complex or fusion protein; and

(b) detecting if the candidate antibodies or fragments thereof bind the IL-B30 or p40 subunit, and selecting the antibody or fragment thereof that does not bind the IL-B30 or p40 subunit.

6. The method of claim 5 wherein said antibody or fragment thereof is selected by immunoselection or immunodepletion.

7. The method of claim 5 , wherein said antibody or fragment thereof is a humanized antibody, monoclonal antibody, single chain antibody, Fv fragment, Fab fragment, Fab′ fragment, or F(ab′)2 fragment.

8. The method of claim 5 , wherein said antibody is a neutralizing antibody.

9. The method of claim 5 , wherein the fusion protein comprises, from the N-terminus to the C-terminus, mature IL-12 p40, a linker, and mature IL-B30.

10. The method of claim 5 , wherein said antibody or fragment thereof is detectably labeled.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →